Alzheimer's disease (AD) is the most common form of dementia in aging adults. The diagnosis is still primarily made on the basis of history and physical and neurologic examinations. The incidence increases rapidly with age, so the number of affected individuals with AD is ballooning rapidly. Cholinesterase inhibitors are mildly effective in treating cognitive and global functioning, as well as behavior abnormalities in patients with mild-, moderate-, or severe-stage disease. The N-methyl-D-aspartate (NMDA) antagonist memantine is similarly mildly effective alone or in combination with cholinesterase inhibitors in moderate to severe stages of the disease. No therapy is proven to delay disease progression, but recent insights into the pathophysiology of AD have led to promising investigational therapies, including the development of both g-and b-secretase inhibitors as well as active and passive immunization against the amyloid b-protein.
OVERVIEW
Alzheimer's disease (AD) is estimated to be by far the most common form of dementia in the United States, currently afflicting as many as 4.5 million mainly elderly individuals. The incidence doubles every 5 years after the age of 60. As the population over age 80 is exploding, with improvements in health care leading to longer life spans, it is estimated that the prevalence of AD by 2050 will more than triple to 14 million Americans. This illness is far and away the most common neurodegenerative disease and the most common illness leading to nursing home placement, which drives huge economic costs, currently up to $140 billion in health care, nursing home costs, and lost wages and productivity for both family members and caregivers. Available therapies treat symptoms but not the underlying biological disease process. Development of a new therapy delaying either onset of de-mentia or progression of functional deterioration by as little as 1 to 2 years could greatly decrease overall costs both to families and society.
NEUROPATHOLOGY AND PATHOPHYSIOLOGY
In patients with AD, atrophy starts in the entorhinal cortex and hippocampus, and as the illness worsens clinically, loss of brain volume increases and spreads more globally to involve most areas of the cortex except the occipital poles (Figure 2-1) .
Microscopically, in addition to the global loss of neurons, increasing numbers of extracellular amyloid plaques are present. These amyloid plaques have been found to be both ''diffuse'' in character-and these diffuse plaques are thought to be relatively benign because they are frequently found in normal elderly individuals and early in the disease course of AD-and ''compact,'' often associated with neuritic changes caused by toxic effects of the deposited amyloid on surrounding dendrites and axons (Figure 2-2) . Amyloid may also be found diffusely deposited in the walls of cerebral blood vessels. In addition to amyloid plaques, wispy accumulations of an intracellular proteomous material are present, called neurofibrillary tangles (NFTs) (Figure 2-3) . NFTs are made up of paired helical filaments composed of abnormally hyperphosphorylated tau. These are the cardinal features originally described by Alzheimer 100 years ago.
Amyloid plaques have been found to be composed of the b-amyloid proteins 1-40 and 1-42. The b-amyloid 1-40 form is more abundant in plasma and CSF, but the 1-42 variety constitutes most of the cores of these amyloid plaques. The b-amyloid proteins originate from a larger, abundantly expressed transmembrane protein in the brain called the amyloid 40 FIGURE 2-1 Coronal section from autopsied brain of patient with severe-stage Alzheimer's disease, illustrating marked hippocampal atrophy as well as global cortical atrophy.
Courtesy of Dr. Bernardino Ghetti.
KEY POINTS:
A In Alzheimer's disease, wispy accumulations of a proteomous material, called neurofibrillary tangles, are found inside many neurons.
A In Alzheimer's disease, the b-amyloid protein 1-42 constitutes most of the cores of amyloid plaques.
precursor protein (APP). They are generated from APP by b-secretase and g-secretase, which have been recently characterized and are active targets for drug therapy.
Mutations have been found, as will be described later in this chapter, in both the genes coding for the b-amyloid proteins associated with familial AD and for the tau protein associated with frontotemporal dementia (FTD) . Study of the effects of these mutations in cell lines and transgenic animals that develop plaques and tangles has provided insights into how these proteins normally function and how, when disturbed by mutation, their function is altered, leading to dementia. It is hoped that these insights regarding function are also applicable to sporadic AD, and several drugs have been developed to retard production or aid degradation and or clearance of these b-amyloid proteins.
Interestingly, although considerable evidence suggests that b-amyloid and its toxic effects on the brain may play the key role in initiating the pathophysiologic cascade of processes that lead to AD, progression of clinical dementia seems to correlate more closely with numbers of NFTs or loss of synapses.
Clearly a cascade of pathologic processes involving different mechanisms, including free radical formation and inflammation, occurs as AD progresses (Figure 2-4) . Neuronal systems as defined by neurotransmitters are differentially affected. The cholinergic system is particularly susceptible to deterioration, and cholinergic deficiency has been correlated with clinical progression of AD. Similarly, as AD progresses, glutaminergic, noradrenergic, and serotonergic system deficiencies develop and have been associated with further cognitive deterioration and or behavioral abnormalities. Therapeutic efforts during the last 2 decades have largely focused on correcting these 41 KEY POINTS:
A Progression of clinical dementia correlates most closely with the number of neurofibrillary tangles and/or loss of synapses.
A Cholinergic deficiency has been correlated with clinical progression of Alzheimer's disease.
neurotransmitter deficits, and some modest success in improving symptoms has been achieved.
Neuropathologic Criteria for Alzheimer's Disease Cortical extracellular amyloid plaques and intraneuronal NFTs are the basic features of AD, and stereotypic spread of the NFTs, as originally described by Braak and Braak (1991) , provided a basis for staged neuropathologic criteria for AD that remain useful today. The first two stages involve NFTs in entorhinal cortex and adjacent portions of the hippocampus, typically without clinical symptoms. In stages III and IV, NFTs spread to limbic regions, and cognitive deficits develop. In stages V and VI, NFTs spread to other regions of the cortex, and the breadth and severity of cognitive deficits and the dementia progressively worsen. Considerable evidence indicates, however, that plaques and tangles can be found in substantial numbers in many elderly patients with normal cognitive functioning and that overlap exists in plaque and tangle pathology between the very elderly (over age 90) with normal cognition and those who are demented (Bennett et al, 2006) , such that diagnosis on the basis of neuropathologic changes alone in the earlier stages may be difficult. Nonetheless, newer criteria assessing both plaque and tangle densities have evolved. Khachaturian criteria looked at age-related numbers of amyloid plaques in a 1 mm 2 field of the neocortex (Khachaturian, 1985) . The Consortium to Establish a Registry for Alzheimer's Disease criteria consider plaques in three designated brain regions using defined stains (Mirra et al, 1991) . Finally, the Reagan Institute criteria assess both plaques and tangles in a highly specified way and appear to have generally high correlation and utility in practice in confirming diagno-sis and assessing disease stage (Newell et al, 1999) .
EPIDEMIOLOGY
The major risk factor for Alzheimer's disease is aging. Although the illness has been reported to occur in exceedingly rare patients in their 20s and 30s, onset of clinical symptoms in this illness is uncommon until the 50s, with prevalence rapidly increasing to age 65 years when 1% to 2% of the population is afflicted. By age 75 the prevalence is estimated at 15%, and by age 85 it has been estimated to be present in 35% to 50% of the general population, with some studies suggesting the prevalence continuing to climb, such that the majority of individuals in their 90s show clinical signs of at least mild-stage dementia. However, underlying brain pathology in these oldest old with dementia may differ little from age-matched normals other than showing greater neuronal loss, and their disease course may be relatively benign. Therefore, even though they meet current clinical criteria for AD, it is unclear that this subset of the population should really be considered to have the same illness. The second major risk factor for AD is family history, with approximately 20% of patients with AD having one or more siblings or parents affected and a pattern of autosomal inheritance.
In families with AD, several genetic mutations have been identified that seem to be causative for the disease, but most have been associated with presenile forms of the disease. Specifically, a few dozen families have mutations in the APP gene, usually in the region of the gene that codes for the b-amyloid proteins (Goedert and Spillantini, 2006) . It is thought that these mutations cause abnormal b-amyloid metabolism, resulting in chronically higher levels of this protein, which leads to AD. Onset of clinical symptoms typically occurs in the late 30s to 60 years of age. The other mutations causing earlyonset disease have been localized to the presenilin-1 (PS-1) gene on chromosome 14 and the presenilin-2 (PS-2) gene on chromosome 1. Again, only a few dozen families have been found in which PS-2 gene mutations are associated with AD, while more than 160 separate mutations in PS-1 have been found in several hundred families to cause AD and rarely other symptoms such as spasticity or seizures (Goedert and Spillantini, 2006) . The presenilins have been found to operate in a complex that acts functionally as g-secretase (Brunkan and Goate, 2005) . As previously mentioned, this enzyme's complex is critically involved in slicing APP to produce b-amyloid.
Increased levels of b-amyloid have also been found in AD patients with PS-1 or PS-2 mutations (Scheuner et al, 1996) . Overall, these mutations cause less than 1% of all cases of AD. Even in patients with family history under the age of 65, these mutations are causative in less than 10%. An early-onset patient with AD is more likely to have an associated mutation if there is history of multiple other affected family members with age of onset occurring in the same age range. Rather than aid clinical identification of patients, the major significance of these mutations has been to create transgenic animal models that have been exceedingly useful in better understanding disease mechanisms and to develop new drugs and other novel approaches, such as vaccination or antibody administration, to treat the disease.
The major genetic risk factor identified for AD is the APOE polymorphism >4 gene. ApoE is one of the most important cholesterol-and lipid-carrying proteins in peripheral blood. In the brain and CSF compartments, it is the only significant lipid transport protein and also has a second major function as a transport protein for b-amyloid. It comes in types >2, >3, and >4, with the >2 allele being relatively rare. The >4 allele is carried by 15% to 20% of individuals, and the >3 allele by the majority of the rest of the population. The 1% to 2% of individuals who are homozygous for >4 have a 50% risk of symptomatic AD in their mid-to late 60s. Those who are heterozygous or carry one copy of the >4 allele have a 50% risk of developing AD in their midto late 70s (Saunders et al, 1993) . Some data suggest that women heterozygous for >4 are more likely to develop AD at an earlier age than men. Individuals who carry the >3 or >2 alleles are more likely to remain free of developing AD until their 80s or later, if at all. Some evidence suggests that >2 is protective regarding risk for AD. The risk conferred by the >4 allele is similar for both familial and sporadic AD. Determination of APOE genotype in a patient with dementia does improve diagnostic specificity, but it is arguable whether diagnostic accuracy is improved enough to be clinically useful. If subjects are homozygous or heterozygous for >4 and do not convert to AD in the age range for which they are at risk for onset, current evidence is equivocal or negative that their risk is any greater than the general population for developing AD at more advanced ages. Therefore, genetic counseling is not recommended at the current time in APOE >4 subjects concerning their risk for AD. Recently, it has been found that, in individuals with mild cognitive impairment (MCI), the APOE >4 genotype is associated with a much greater risk of conversion to AD over 3 to 4 years after their initial diagnosis of MCI (Petersen et al, 1995) , and >4 subjects appear to have more significant responsiveness to donepezil therapy (Petersen et al, 2005) . Clinical disease progression after conversion to AD,
KEY POINTS:
A Presenilin-1 protein is part of a complex that acts as g-secretase.
A The major genetic risk factor for Alzheimer's disease is the APOE >4 polymorphism.
A It is unclear whether determination of APOE genotype in a patient with dementia improves diagnostic specificity enough to be clinically useful.
however, does not appear to be influenced by APOE genotype, so the ApoE4 protein may act differentially in the very early biological stages of AD, but once the different pathologic mechanisms associated with AD start to cascade, their influence appears to wane. Considerable evidence suggests that other, as yet unidentified, genetic mutations or polymorphisms play a role in increasing risk for earlier age of AD onset.
Other factors associated with differential risk for AD are gender and education. Women are at modestly greater risk for AD, even with adjustment for their greater survival to older ages. In the past, this greater risk for AD has been associated in several epidemiologic studies with postmenopausal estrogen deficiency, and estrogen replacement was thought a potentially valuable primary prevention approach for AD. However, the very large Women's Health Initiative Memory Study of estrogen in elderly women has shown that estrogen replacement may increase, rather than decrease, the risk for AD (Rapp et al, 2003; Shumaker et al, 2003) .
In several studies increased education has been associated with reduced risk for AD or later onset of dementia. An attractive hypothesis has been that better-educated individuals have a cognitive reserve, so biological disease progression must progress further before the reserve is overcome and clinical symptoms begin to develop. However, cognitive training or mental exercises have not been demonstrated to be protective in those at risk or to delay disease progression in those affected with the illness. Interestingly, several studies have suggested that physical exercise may be protective or delay disease progression.
Epidemiologic studies and very preliminary pilot trials suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent or delay progression in AD; several large double-blind, placebo-controlled trials, however, have indicated no significant reduction in risk for AD with NSAIDs and, rather, a significant increased risk for gastrointestinal symptoms, such as hemorrhage and cardiovascular disease, including stroke (Aisen et al, 2003; Maillard and Burnier, 2006) .
Head trauma has been suggested as a risk factor for AD, but studies have been muddled by wide differences in reported series in the criteria applied to define significant previous head trauma history. Further, APOE >4 patients have been demonstrated to recover less well from head trauma, so the greater manifestations of trauma may be a pseudomarker for APOE >4 inheritance, which is a risk factor for AD (Jellinger, 2004) .
More recently, a wealth of data from various studies has suggested a strong association between the metabolic syndrome and increased risk for AD (Martins et al, 2006) . Specifically, diabetes mellitus, insulin resistance, high cholesterol, hypertension, reduced exercise, and obesity are all risk factors with some association for AD. This is an area of active investigation, with numerous trials seeking to determine whether improving or treating these factors individually will reduce conversion to or delay progression of AD. It remains to be determined whether the glitazones, statins, or exercise as preventive measures for AD have significant reproducible beneficial effects in prospective studies, and these approaches, although good for general health and the reduction of vascular disease, cannot currently be recommended to prevent or treat AD. The DSM-IV criteria are the broader and more general of the two sets, essentially requiring insidious and progressive cognitive memory and cognitive impairment where other potential causes have been excluded (Table 2-1).
DIAGNOSTIC CRITERIA
NINCDS-ADRDA criteria for ''definite AD'' require clinical features for probable AD and autopsy confirmation. A diagnosis of ''probable AD'' requires deficits in two or more areas of cognition, including memory, that are progressively worsening, confirmed by clinical and neuropsychological evaluations, and not associated with either delirium or other brain or systemic illnesses that could be the cause of the dementia. Onset is between 40 and 90 years of age ( Table 2 -2). The diagnosis is further supported by impaired function in activities of daily living (ADLs) and presence of behavioral dysfunction, and family history (particularly if supported by previous neuropathology). Other features include supportive laboratory results. A diagnosis of ''possible AD'' includes cases where there is a single progressively more severe cognitive deficit, a second brain or systemic cause for dementia, and atypical onset (early or with unusual symptoms and course [rapid or stuttering]). Both DSM-IV and NINCDS-ADRDA criteria rely heavily on history and the neurologic examination, and recent evidence suggests that both exclude broad populations of patients in very early stages of the disease process who may be more responsive to therapies and have much to gain. Most of these individuals are currently being labeled as having ''mild cognitive impairment,'' an entity whose criteria are still being debated. There is recent interest in determining whether a new broader, more expansive, yet still specific set of criteria for AD that will Absence of systemic disorders or other brain diseases that could account for the dementia
II. A PROBABLE Alzheimer's disease diagnosis is supported by:
Progressive deterioration of specific cognitive functions such as language (aphasia), motor skills (apraxia), and perception (agnosia) Impaired activities of daily living and altered patterns of behavior Behavioral disturbances in AD are very common, occurring in a large majority of patients and becoming more common as the illness progresses. Apathy may occur in early-stage patients who demonstrate marked loss of initiative compared with their previous level of drive or interest. As many as 30% of patients with early-or mild-stage AD will have significant depressive symptoms, including loss 
Neurologic Examination
Two major components are important in examining the dementia patient: (1) a general physical and neurologic ex-amination to look for signs that might point toward other causes of dementia, as well as to document any findings that may relate directly to AD; and (2) mental status testing to document presence of cognitive deficits supporting dementia diagnosis, to begin staging the illness, and to determine whether more extensive neuropsychological testing might be indicated to better characterize the illness.
The physical and neurologic examinations are very helpful to support the diagnosis of AD. Despite the recent popularity of promoting AD as a diagnosis that is positively made on clinical features in the differential diagnosis process, it still very much today remains a diagnosis of exclusion. The focus of these examinations in determining a diagnosis of AD is to exclude other possible dementias. The physical examination provides a brief screen to exclude other organ system problems as the source of the patient's cognitive impairment. The general neurologic examination may often be normal in the demented patient with AD (Case 2-1), but the presence of focal deficits, eg, visual field cuts, weakness or spasticity in an arm or leg, suggests a vascular cause for dementia. Older series have reported signs of Parkinson's disease in as many as 10% to 30% of patients with AD. With recent inclusion of immunohistochemistry in neuropathologic studies in large series of patients with dementia, and clinicopathological correlation, it has become clear that many, if not most, of these patients have diffuse Lewy body disease and/or Parkinson's disease with dementia.
Gait or balance impairment may also indicate Binswanger's disease (a form of vascular dementia associated with multiple lacunar subcortical strokes), normal pressure hydrocephalus, or progressive supranuclear palsy. Continuing gait problems can also occur in the later
KEY POINT:
A As Alzheimer's disease progresses, agitation is eventually found in up to 75% of patients.
" ALZHEIMER'S DISEASE stages of AD, leading to substantially increased risk for falls. Myoclonus in early-stage dementia is worrisome for Creutzfeldt-Jakob disease or other prion diseases, whereas it may be found later in the disease course in 5% to 10% of patients with AD. The list of neurologic findings that may suggest possible, if rarer, etiologies for a patient's dementia is quite extensive. In general, clues from the history and physical examination guide any additional laboratory testing outside the standard dementia evaluation.
Mental status testing varies in its breadth and depth according to the preferences of the individual physician. In general, assessment should include level of alertness or attention, orientation (person, place, time),
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Case 2-1 A 78-year-old woman lives alone but is accompanied to the appointment by her sister, who contributes history. The patient reports progressive loss of memory over the last year. Specifically, she will read the newspapers or magazines and forget what she has read. Her sister will say something to her, and she will immediately forget what was said. She makes ''to-do'' lists constantly, but then loses them. She has been confused in paying bills, and after being unable to figure her taxes, her son found her financial records to be in a mess. Most recently she became lost while driving to her sister's house, which was less than 2 miles away, and her son needed to drive to a gasoline station to lead her home. The onset of her symptoms is described as gradual. There is no history of previous stroke or depression.
Her medications include aspirin 81-mg tablet for cardioprotection, lisinopril and atenolol for hypertension, lovastatin for hypercholesterolemia, and a stool softener for constipation.
Her review of systems is significant only for some fluctuation in weight and loud snoring.
She was previously a social worker, is living alone, but is seen frequently by her sister. She has 16 years of education. She was a smoker but quit in 1970 and never has consumed alcoholic beverages.
Her family history reveals that one of her four living sisters has been clinically diagnosed with AD.
Her physical examination is normal. Mental status testing reveals that she is alert and oriented to name only. Her affect is appropriate. On Mini-Mental State Examination (MMSE) she scores 22/30, missing all three words on recall. Her fluency is within normal limits. She has difficulty in doing simple additions and subtractions and in spelling world backwards. Her Geriatric Depression Scale (15-items version) score is 2, which is within normal limits (Sheikh and Yesavage, 1986) . Her neurologic examination, including cranial nerves, motor strength, deep tendon reflexes, and gait, is entirely within normal limits. MRI studies of her head reveal only mild atrophy. Her complete blood count, electrolytes, glucose, thyroid function tests, B 12 , and folate levels are normal.
Comment. The most prominent deficit appears to be, by both history and examination, short-term memory, but she clearly also has difficulties with calculation and multistep tasks as well as orientation that have recently begun to impair her function in instrumental ADLs. With normal laboratory testing, including MRI, excluding other possible causes, her most likely diagnosis is AD.
short-term and remote memory (remembering three words for 5 minutes and knowledge of their birth date and high school), language, visuospatial functioning (copying figures), calculation, and executive functioning or judgment. The MMSE has been most widely used to screen for cognitive dysfunction to support the diagnosis of dementia and to stage the dementia ( Ease of administration leads to rapid spread of its use " ALZHEIMER'S DISEASE relatively insensitive to measuring change in the dementia patient. Nonetheless, widespread familiarity and use by physicians is a powerful force, and the MMSE is unlikely to be displaced in its assessment role anytime soon. It is, therefore, important that clinicians who use it remember its limitations. Clock drawing is a similarly useful very short screen for cognitive impairment or dementia (Brodaty and Moore, 1997). It is easy for physicians to administer and score. Interestingly, for such a simple test, at least a dozen different ways to score performance on the drawing have been proposed, and all seem to be valid, correlating well with other tests assessing cognitive impairment in dementia. Finally, the Functional Assessment Questionnaire, although not part of mental status assessment, is given to the caregiver or family member and helps document the patient's deficits in performing ADLs that are secondary to cognitive impairment (Table 2-4) (Pfeffer et al, 1982) .
Laboratory Studies
It has been estimated that more than 95% of dementia in elderly persons is caused by neurodegenerative or ischemic illnesses that are not reversible. The focus of laboratory evaluations has been to first and primarily identify the small minority of patients who have reversible causes for their dementia (Table 2-5) (Farlow and Hake, 2002) . In reality, a potentially reversible cause may be identified in 25% to 40% of patients, but when the laboratory abnormality is corrected or an offending drug (anticholinergics, pain medication) is withdrawn, only transient mild improvement or stabilization in disease progression ensues. Over the longer term the patient still has progressive dementia, most often AD. Nonetheless, any improvement in cognitive functioning or function in ADLs, even if limited or transient, is greatly appreciated by patients and their caregivers, and the benefits fully justify doing an evaluation for reversible conditions.
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A second purpose of the laboratory evaluation is to aid differential diagnosis among the irreversible types of dementia (AD, Lewy body or Parkinson's dementias, vascular dementia, frontotemporal dementias [FTDs] ). Correct diagnosis about the type of dementia can assist in the counseling of patients and providing appropriate information for the caregiver about cause and prognosis, particularly in regard to ultimate nursing home placement and mortality. Accurate dementia classification will also be important in choosing appropriate therapy. In practice, double-blind, placebo-controlled trials-based evidence supports some efficacy for available drugs in all of the above degenerative and vascular forms of dementias except FTD.
In screening for reversible causes of dementia, space-occupying masses or other structural abnormalities may be identified by brain imaging studies such as CT or MRI. Common abnormalities identified would include strokes or ischemic changes, normal pressure hydrocephalus, subdural hematomas and hygromas, tumors such as large meningiomas, and gliomas or brain metastases from primary tumors elsewhere that may not have been previously identified.
Selective frontal and/or temporal atrophy on MRI or CT may indicate FTD, or multiple large vessel or smaller subcortical strokes may be identified that would support diagnosis of vascular dementia. Both of these irreversible dementias may be differentiated from AD. The ability to reasonably discriminate FTD from AD in individual patients may be difficult on the basis of clinical examination and standard CT or MRI structural imaging. Functional imaging measuring blood flow or metabolism by SPECT or PET may be better able to discriminate FTD from AD and/or other forms of dementia.
Metabolic abnormalities worsen cognitive deficits in patients with dementia. Relatively minor deviations out of the normal range can exacerbate mental impairment in some individuals. Potentially reversible causes might include: o Hypokalemia and hyperkalemia:
The former might occur, for example, in many elderly patients taking diuretics for treatment of hypertension or congestive heart failure, as well as in individuals taking steroids. o Hypernatremia and hyponatremia:
The former may be found in association with dehydration, which can occur in impaired elderly patients who are dependent on others for fluid intake. The latter may occur in association with a variety of chronic illnesses and/or medications. Hypocalcemia and hypercalcemia are found more rarely but also can affect cognitive functioning and should be screened for. (Farlow and Hake, 2002) .
BIOLOGICAL MARKERS AND DISEASE PROGRESSION
No biomarkers currently reliably aid in the diagnosis of AD or have been shown to reliably measure disease progression. The best-validated test is structural MRI, where progressive atrophy in the hippocampus and loss of whole brain volume have shown good correlation with progression of clinical symptoms ( Jack et al, 2000) . This methodology is widely used as a secondary measure to support clinical drug trials (Figure 2-5 FIGURE 2-5 MRI study with coronal view through the hippocampal region illustrating moderately severe medial temporal atrophy and milder global atrophy typical for Alzheimer's disease.
Courtesy of Dr. Andrew Saykin.
spectroscopy and 18-fluorodeoxyglucose PET exhibit changes associated with AD (see Figure 2 -6 for PET in AD), but lack of longitudinal data using these techniques and their high costs have prevented their general adoption in clinical practice. Ab1-42 protein levels in CSF from patients with AD have consistently been found to be lower than in agematched controls (Andreasen et al, 1999) . Similarly, tau protein levels and phospho-tau levels are significantly higher in patients with AD than in normal elderly patients (Blennow, 2004) . Unfortunately, abnormal Ab and tau levels occur in other neurodegenerative conditions, and some overlap occurs with normal aging. Combining these two measures improves accuracy of diagnosis, but it remains unclear that CSF Ab and tau measurements improve specificity of clinical diagnosis enough to justify this procedure in the majority of patients. In general, biological markers of AD and of disease progression have limitations and, therefore, have not been broadly adopted in practice (Thal et al, 2006) . Ultimately, proteomic studies in plasma and CSF in large prospective longitudinal clinical studies, such as the Alzheimer's Disease Neuroimaging Initiative, may yield more sensitive and specific biological markers for AD.
TREATMENT
Current therapies for AD are primarily symptomatic, focused on treating either cognitive or behavioral symptoms. None has been proven to delay biological progression of disease. The development of therapies that will delay the disease progression in 54 FIGURE 2-6 Views from PET study using 18-fluorodeoxyglucose obtained in a patient with Alzheimer's disease.
The image demonstrates decreased signal or metabolism in the posterior parietal regions as may characteristically be seen with this illness.
Courtesy of Dr. James W. Fletcher. " ALZHEIMER'S DISEASE affected subjects or primarily prevent its onset in normal older adults remains a critical, but thus far elusive, goal. The currently available symptomatic therapies for AD mildly improve deficits in cognition and function in ADLs and global functioning, as well as delay onset of or slightly improve behavioral symptoms ( Table 2 -6) . In general, beneficial effects are seen in a significant minority of patients, and stabilization of symptoms or temporary lessening of symptomatic decline are seen in others. Benefits may be subtle and may be difficult to judge against a background of disease progression. Caregivers need to be advised to have realistic expectations, and any benefits need to be weighed against adverse effects that may occur in determining an appropriate dose or deciding whether to continue therapy with a particular drug.
Cholinesterase inhibitors were developed as a treatment after recognition that cholinergic deficiency worsens 55 in parallel with deterioration of memory and other cognitive functioning. Donepezil is an inhibitor more selective for acetylcholinesterase; rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase; and galantamine, in addition to inhibiting cholinesterase, apparently modulates stimulation at nicotinic receptors. The clinical significance of these differences, if any, remains to be proven (see Table 2 -7 for the cholinesterase inhibitors' different characteristics). Double-blind, placebo-controlled trials have demonstrated that donepezil, rivastigmine, and galantamine have the potential to mildly improve cognition, function in ADLs, and behavior in patients with mild-to moderate-stage AD for periods of between 6 and 18 months (Doody et al, 2001) . Donepezil has recently also been demonstrated to be effective for treating patients with moderate-to severestage dementia ( All the acetyl cholinesterase inhibitors need to be titrated during initiation to avoid adverse effects and to achieve the best dose to maximize benefits ( Table 2- 8) . If adverse effects do occur, doses may be skipped or drug dosage reduced until the negative effects disappear, and higher dosage may be again tried at a later date. In general, positive effects on cognition, function in ADLs, and behavior may be countered by adverse side effects such as nausea, vomiting, and diarrhea, which also become more likely with dosage increases. Finding the most favorable balance between these drug effects in the individual patient is the goal. If patients do not tolerate one cholinesterase inhibitor, they may tolerate another, so that patients may be switched to try at least one alternative drug.
Both the AD 2000 Collaborative Group study and the Alzheimer's Disease Cooperative Studies-Mild Cognitive Impairment Trial suggested that donepezil may be less effective after 18 to 24 months (Courtney et al, 2004; Petersen et al, 2005) . Neuropathologic studies, however, suggest that the central cholinergic deficiency in MCI may be less pronounced than in AD
KEY POINTS:
A Donepezil, rivastigmine, and galantamine have, in double-blind, placebocontrolled trials, been demonstrated to improve cognition, function in activities of daily living, and behavior in patients with Alzheimer's disease.
A All cholinesterase inhibitors need to be titrated during initiation to achieve the best dose. " ALZHEIMER'S DISEASE (DeKosky et al, 2002) , and the AD 2000 study had a variety of methodological issues, including periodic withdrawal, that cast doubt on these results. Substantial open-label followup data are available for all these drugs, suggesting continued effectiveness for 4 or 5 years or longer. However, these data are uncontrolled and likely biased by selective dropouts. Another topic of considerable interest to families and physicians is when to withdraw these drugs. As a general principle, these drugs should be stopped when the patient is no longer benefiting from their use, but this may be difficult to determine in latestage individuals. In severely affected patients, the drugs should be withdrawn when patients are no longer able to meaningfully interact with family or caregivers. Memantine belongs to a second class of drugs that works by antagonizing glutamate at the NMDA receptor, potentially improving signal transmission, and by preventing excess calcium to rush into the neurons with glutamate stimulation, thus providing neuroprotection ( Table 2- 8) . In patients with moderate-to severe-stage disease, memantine mildly improves cognitive deficits, function in ADLs, and behavior. Adverse effects with memantine are fewer than with the cholinesterase inhibitors, and one large doubleblind, placebo-controlled trial in patients previously taking donepezil suggested additive symptomatic benefits when memantine was added. Trials in patients with milder-stage AD have shown a trend toward beneficial effects with memantine, but benefit was of relatively small magnitude and inconsistently demonstrated across the clinical domains. Memantine is currently not recommended for use in milder-stage AD. With memantine, as with the cholinesterase inhibitors, symptomatic benefits may be difficult for caregivers to judge in some patients and so they should be counseled regarding realistic expectations for this therapy. As with the cholinesterase 57 Start once-daily oral therapy at 5 mg/d, in the morning with or without food, and after 4 to 6 weeks, increase to 10 mg/d to maximum dosing as tolerated. The minimum therapeutic dose for donepezil is 5 mg/d.
Rivastigmine
Start oral therapy at 1.5 mg 2 times a day, taken with full meals in the morning and evening, with stepwise increments at monthly or greater intervals to 3 mg 2 times a day, 4.5 mg 2 times a day, and 6 mg 2 times a day (maximum). The minimum therapeutic dose is 6 mg/d. If treatment is interrupted for more than 1 week, the 1.5-mg 2-times-a-day dose should be reinstated and titration repeated.
Galantamine Start once-daily oral therapy at 8 mg/d, taken with full meals in the morning with monthly increase to 16 mg/d, and if tolerated 24 mg/d as the maximum dose.
The minimum therapeutic dose is 16 mg/d. If treatment is interrupted for more than 1 week, the drug should be restarted at the 8 mg/d dose and titration should be repeated.
Memantine
Start once daily at 5 mg/d with or without food. At 1-week intervals, the dose should be titrated up in 5-mg increments to 10 mg/d (5 mg 2 times a day), then to 15 mg/d (separate 5-mg and 10-mg doses), and finally to 10 mg 2 times a day.
inhibitors, memantine should be continued until it is judged to be no longer benefiting the patient or until there is no meaningful interaction between the patient with AD and the family or caregivers.
Evidence Against Previously Accepted Therapies Vitamin E was originally found in patients with moderate-to severe-stage AD to delay functional deterioration, nursing home placement, and death by approximately 25% in a large doubleblind, placebo-controlled trial (Sano et al, 1997) . However, no cognitive benefits were seen in the group taking vitamin E. Also, the vitamin E group in the Alzheimer's Disease Cooperative Study Group-MCI study showed no benefit versus placebo (Petersen et al, 2005) . Recent studies have suggested at least theoretical risks concerning thrombosis with the 2000 U vitamin E dose. Enthusiasm for use of vitamin E has, thus, waned considerably. Several recent double-blind, placebocontrolled studies with negative results argue against the use of estrogens or NSAIDs, both of which may actually have greater risks than benefits in subjects with AD (Aisen et al, 2003; Maillard and Burnier, 2006) .
Future Trends in Alzheimer's Disease Therapy
Most efforts to develop drugs that will delay disease progression have recently focused on reducing amyloid and potentially halting or reversing formation of plaques in the brain. An understanding of this protein's metabolism has led to the development of band g-secretase inhibitors that are effective in reducing plaques in transgenic AD mouse models. However, a potentially adverse effect of g-secretase inhibitors on notch signaling (Barten et al, 2006) and the potential for b-secretase inhibitors to adversely affect central and/or peripheral myelinization (Willem et al, 2006) , suggest caution regarding their development. Human trials are actively proceeding, but these potential safety issues suggest that optimism should be tempered.
In an entirely different approach, vaccination using the b-amyloid protein proved effective initially in reducing b-amyloid plaques in transgenic animals, and a similar vaccine was tested in a large phase 2 trial (Orgogozo et al, 2003) . This large vaccination trial was interrupted when a number of subjects developed encephalitis (Nicoll et al, 2003) . However, autopsy in patients who later died showed apparent clearance of b-amyloid plaques from large areas of the cortex. Very active efforts are proceeding with more targeted approaches using a revised vaccine and monoclonal antibodies to Ab that are expected to avoid the adverse effects seen with the previous vaccination studies.
In summary, several of the antiamyloid approaches currently under development show considerable promise of working, with acceptable side effects. It remains to be determined, however, whether this approach will successfully stabilize or reverse clinical symptoms of AD or rather that these patients with AD will continue to suffer progressive deterioration despite a lack of plaque formation. If the latter proves true, other strategies, possibly focusing on tau protein, will need to be more intensively pursued for developing future therapies.
Treatment of Behavioral Symptoms
Behavioral disturbances are common in AD and become progressively more frequent as the illness progresses, particularly in the more moderate and severe stages ( " ALZHEIMER'S DISEASE discussion.) Abnormalities in the cholinergic and glutaminergic systems are associated with cognitive impairment in AD, but as the illness progresses, multiple abnormalities in other neurotransmitter systems can be demonstrated that may contribute to onset of behavioral or psychiatric symptoms (Aarsland et al, 2005) . As examples, aggressiveness (a component of agitation) has been associated with dysregulation in the g-aminobutyric acid-ergic, serotonergic, and noradrenergic systems, and depressive symptoms have been associated with loss of neurons in both the medium raphe nuclei and locus ceruleus and consequent depletion of serotonin and noradrenalin. Treatment approaches have been loosely directed by this data. Major disorders seen in patients with AD include agitation, depression, anxiety, and insomnia or disturbances in day-night sleep cycles. Treatment of these symptoms in patients with AD can be challenging, and none of the currently available drugs is approved by the US Food and Drug Administration for treating behavioral symp-toms in AD. General principles are listed in Table 2-10 .
Double-blind, placebo-controlled trials are limited, but available data suggest that substantial placebo effects occur with most of these indications and that many commonly used drugs have modest real effects, at best. Nonetheless, treatment of behavioral symptoms is of great importance to family members and caregivers because these symptoms tend to be most difficult for them to manage and are one of the principal factors other than urinary or bowel incontinence leading to nursing home placement.
Aggressive or assaultive behaviors are relatively common in AD with physical attacks occurring in roughly 20% of patients in the community and up to 50% of nursing home patients. Verbal attacks are reported to occur in 50% of patients with AD. Hallucinations occur in as many as 30% of patients at home and 50% in nursing homes. Delusions are even more common, occurring at some time in the illness in 75% of patients with AD. Agitation, hallucinations, delusions, as well as paranoia, may occur in the AD patient with changes in the environment, such as being moved to a new locale, having a new caregiver, having infection, or simply as the result of disease progression. Target symptoms for treatment should be identified before therapy is begun. A recent comparative study suggests very limited efficacy for the most commonly used drugs for agitation (Schneider et al, 2006) . The atypical neuroleptics, despite recent evidence suggesting some increased risk of stroke with chronic use, are still most useful in patients with AD for treating agitation. Treatment may begin with risperidone 0.25 mg, olanzapine 2.5 mg, quetiapine 25 mg, aripiprazole 5 mg, or ziprasidone 20 mg, with each alternative initiated once a day and used with increasing frequency or dosage until 59 
Depression
Symptoms of depression are present in as many as 30% of patients with AD, often at earlier stages of the illness.
The SSRIs are useful for depression associated with AD, but often at lower doses than used in the general elderly population to avoid adverse effects. Choices would include citalopram, escitalopram, fluoxetine, or sertraline. In AD patients with depressive symptoms and poor appetite or weight loss, mirtazapine may be useful. If one SSRI fails to improve symptoms after a reasonable-length trial (4 to 6 weeks), it should be discontinued and another SSRI may be started. If the SSRIs in one or two trials fail to improve symptoms, drugs with combined mechanisms of action involving two or more different neurotransmitter systems, such as venlafaxine or duloxetine, may be given a trial (see Table 2 " Exclude other acute or chronic illnesses. " Exclude potential causes for pain that may be difficult to diagnose and treat in the patient with severe dementia.
" Investigate for changes in patient's caregiver, living arrangements, or general routine.
" Identify and monitor target symptoms. " Avoid drugs for treating behavioral abnormalities with anticholinergic side effects whenever possible.
" Start medications for treating behavioral problems ''low'' and go ''slow.'' Too large a dose or rapid escalation will be very likely to cause adverse side effects in this population.
" When behavioral abnormalities are well controlled by a medication, reduce dose and withdraw medication as soon as possible.
" ALZHEIMER'S DISEASE other area of their body, foot tapping, or repetitive verbalization or whistling, it should be determined whether this behavior is disturbing to the patient or the caregiver and whether it is interfering with the patient's ability to function in ADLs. If the answer is yes, drug treatment is an option. These symptoms sometimes will respond to one of the SSRIs. The atypical antipsychotics and antianxiety drugs, such as alprazolam, lorazepam, or diazepam, may also be useful but are frequently too sedating for chronic use (see Table 2 -11 for a list of alternatives). Lorazepam (Ativan) 0.5 mg to 2.0 mg up to tid Fatigue, memory impairment, nausea, incoordination, vomiting, constipation, blurred vision, sexual dysfunction and decreased drive tid = 3 times a day; bid = 2 times a day.
*Increased mortality has been seen generally with the atypical neuroleptics in elderly patients with psychosis.
Insomnia or Day-Night Sleep Cycle Disturbances
Insomnia may be responsive to trazodone or alprazolam or the other benzodiazepines, all of which should be used in as low a dose as possible and for the briefest period as necessary to control symptoms. Zolpidem may be helpful, but carryover sedation may be present the next morning. " ALZHEIMER'S DISEASE Eszopiclone also may be helpful and in younger patients seems to cause less carryover drowsiness the next day, although this is yet to be confirmed in an AD population study (see Table 2 -13 for a list of alternatives). A report suggesting that b-secretase may have a major normal role in controlling myelination and suggesting caution in developing inhibitors of this enzyme to treat AD.
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